Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review-Reference-Cited by-同舟云学术

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

Published:2011-11-03 Issue:3 Volume:132 Page:895-915
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Luporsi Elisabeth,André Fabrice,Spyratos Frédérique,Martin Pierre-Marie,Jacquemier Jocelyne,Penault-Llorca Frédérique,Tubiana-Mathieu Nicole,Sigal-Zafrani Brigitte,Arnould Laurent,Gompel Anne,Egele Caroline,Poulet Bruno,Clough Krishna B.,Crouet Hubert,Fourquet Alain,Lefranc Jean-Pierre,Mathelin Carole,Rouyer Nicolas,Serin Daniel,Spielmann Marc,Haugh Margaret,Chenard Marie-Pierre,Brain Etienne,de Cremoux Patricia,Bellocq Jean-Pierre

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-011-1837-z.pdf

Reference116 articles.

1. Aleskandarany MA, Green AR, Rakha EA, Mohammed RA, Elsheikh SE, Powe DG, Paish EC, Macmillan RD, Chan S, Ahmed SI, Ellis IO (2010) Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. Int J Cancer 126:1176–1761. doi:10.1002/ijc.24860

2. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR (2010) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 127:591–599. doi:10.1007/s10549-010-1028-3

3. Andreetta C, Puppin C, Minisini A, Valent F, Pegolo E, Damante G, Di Loreto C, Pizzolitto S, Pandolfi M, Fasola G, Piga A, Puglisi F (2009) Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 20:265–271. doi:10.1093/annonc/mdn592

4. Assersohn L, Salter J, Powles TJ, A’Hern R, Makris A, Gregory RK, Chang J, Dowsett M (2003) Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82:113–123

5. Bartlett JMS, Munro A, Cameron Da, Thomas J, Prescott R, Twelves CJ (2008) Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. J Clin Oncol 26:5027–5035

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer;Annals of Surgical Oncology;2024-09-09

2. The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with In Situ or Early-Stage Invasive Breast Cancer;International Journal of Molecular Sciences;2024-09-04

3. Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-08-18

4. Pathological Underestimation of Core Needle Biopsy Risks in Ductal Carcinoma In Situ Breast Cancer Diagnosis: a Predictive Nomogram;2024-04-08

5. Clinical Characteristics and Prognostic Markers of Aggressive Subtypes of Thyroid Cancer: A Retrospective Chart Review Study;2024-03-21